Paradigm reports osteoarthritis pain reduced by 50%
Filed with ASX · · 3 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Half Year Accounts
- Quarterly Update and Appendix 4C
- PARs European Patent Granted for Bone Marrow Edema Lesions
- Paradigms Two Arthritis Phase 2 Clinical Trials on Schedule
- Paradigms ACL Phase 2 Clinical Trial Success
Later from Paradigm Biopharmaceuticals
- Paradigms phase 2 clinical data update
- Paradigm OA Phase 2b Clinical Trial over 80% Recruited
- PAR - 50% reduction in osteoarthritis pain maintained
- PAR achieves 100 per cent recruitment in Phase 2b OA Trial
- PAR achieves 60 per cent reduction in osteoarthritis pain
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals